Microbiome and intestinal pathophysiology in post-acute sequelae of COVID-19

[1]  Guohui Fan,et al.  6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2023, The Lancet.

[2]  Yan Xie,et al.  Long-term gastrointestinal outcomes of COVID-19 , 2023, Nature Communications.

[3]  M. El-Daly,et al.  Analysis of the nasopharyngeal microbiome and respiratory pathogens in COVID-19 patients from Saudi Arabia , 2023, Journal of infection and public health.

[4]  G. Nicolson,et al.  Long COVID and the Neuroendocrinology of Microbial Translocation Outside the GI Tract: Some Treatment Strategies , 2022, Endocrines.

[5]  Elizabeth B White,et al.  Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia , 2022, Nature Communications.

[6]  T. Miyoshi‐Akiyama,et al.  Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications , 2022, Gastroenterology.

[7]  S. Ng,et al.  Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance , 2022, Gut.

[8]  Alese E. Halvorson,et al.  Associations Between Gastrointestinal Symptoms and COVID-19 Severity Outcomes Based on a Propensity Score–Weighted Analysis of a Nationwide Cohort , 2022, Gastro Hep Advances.

[9]  J. Rosmalen,et al.  Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study , 2022, The Lancet.

[10]  P. Bieniasz,et al.  Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection , 2022, Gut microbes.

[11]  M. Timko,et al.  Dynamic Alterations in the Respiratory Tract Microbiota of Patients with COVID‐19 and its Association with Microbiota in the Gut , 2022, Advanced science.

[12]  M. Peluso,et al.  Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling , 2022, JCI insight.

[13]  H. Nakaya,et al.  Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells , 2022, eLife.

[14]  P. Mudd,et al.  The salivary and nasopharyngeal microbiomes are associated with SARS‐CoV‐2 infection and disease severity , 2022, bioRxiv.

[15]  H. Tilg,et al.  Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases , 2022, Gastroenterology.

[16]  Guojun Wu,et al.  Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome , 2022, mBio.

[17]  N. Curtis,et al.  The Challenge of Studying Long COVID: An Updated Review , 2022, The Pediatric infectious disease journal.

[18]  Yuanting Zheng,et al.  Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients , 2022, BMC Medicine.

[19]  G. Blanco-Fernández,et al.  Decreased Long‐Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019 , 2022 .

[20]  Jordi Espadaler Mazo,et al.  Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial , 2022, Gut microbes.

[21]  B. Beghé,et al.  Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome , 2022, Open forum infectious diseases.

[22]  Nikhil Vatti,et al.  Long-Term Effects of COVID-19 , 2022, Mayo Clinic Proceedings.

[23]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[24]  S. Ng,et al.  Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome , 2022, Gut.

[25]  Virgile Richard,et al.  Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters , 2021, Gut microbes.

[26]  Shiliang Liu,et al.  Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapies , 2021, Reviews in medical virology.

[27]  G. Monteleone,et al.  Long COVID in Inflammatory Bowel Diseases , 2021, Journal of clinical medicine.

[28]  S. Islam,et al.  De novo inflammatory bowel disease is a potential post-acute sequela of SARS-CoV-2 infection , 2021, The Southwest Respiratory and Critical Care Chronicles.

[29]  A. Dagens,et al.  Characterising long COVID: a living systematic review , 2021, BMJ Global Health.

[30]  S. Ng,et al.  Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope? , 2021, Gastroenterology.

[31]  V. Bucci,et al.  Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID , 2021, JCI insight.

[32]  P. Edison,et al.  Long covid—mechanisms, risk factors, and management , 2021, BMJ.

[33]  S. Kent,et al.  Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.

[34]  A. Bhalla,et al.  The Conundrum of ‘Long-COVID-19ʹ: A Narrative Review , 2021, International journal of general medicine.

[35]  M. Ranieri,et al.  The lower respiratory tract microbiome of critically ill patients with COVID-19 , 2021, Scientific Reports.

[36]  H. Harapan,et al.  Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis , 2021, F1000Research.

[37]  Lanjuan Li,et al.  Six-month follow-up of gut microbiota richness in patients with COVID-19 , 2021, Gut.

[38]  Jarvis T. Chen,et al.  Sex Disparities in COVID-19 Mortality Vary Across US Racial Groups , 2021, Journal of General Internal Medicine.

[39]  T. Ayer,et al.  Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-related Liver Disease: A Modelling Study , 2021, medRxiv.

[40]  D. Kao,et al.  Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic , 2021, International journal of molecular sciences.

[41]  O. Werz,et al.  SARS-CoV-2 Causes Severe Epithelial Inflammation and Barrier Dysfunction , 2021, Journal of Virology.

[42]  F. Akar,et al.  Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. , 2021, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[43]  E. Playford,et al.  Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline , 2021, BMJ.

[44]  A. V. Raveendran.  Long COVID-19: Challenges in the diagnosis and proposed diagnostic criteria , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[45]  H. Dweep,et al.  Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients , 2021, Frontiers in Immunology.

[46]  R. Chandler,et al.  The impact of COVID-19 among Black women: evaluating perspectives and sources of information , 2020, Ethnicity & health.

[47]  M. Jenkinson,et al.  Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge , 2020, EClinicalMedicine.

[48]  F. Bruyère,et al.  Follow-up of adults with noncritical COVID-19 two months after symptom onset , 2020, Clinical Microbiology and Infection.

[49]  M. Spruit,et al.  Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? , 2020, ERJ Open Research.

[50]  Jiao Li,et al.  Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study , 2020, Clinical Microbiology and Infection.

[51]  Jun Sun,et al.  Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19 , 2020, Genes & Diseases.

[52]  S. Ng,et al.  Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity , 2020, Microbiome.

[53]  S. Villapol.  Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome , 2020, Translational Research.

[54]  Li Chunxi,et al.  The Gut Microbiota and Respiratory Diseases: New Evidence , 2020, Journal of immunology research.

[55]  Huanming Yang,et al.  The trans-omics landscape of COVID-19 , 2020, Nature Communications.

[56]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[57]  H. Tilg,et al.  Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic , 2020, Gut.

[58]  H. Sokol,et al.  Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection , 2020, Cell Reports.

[59]  S. Ng,et al.  Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge , 2020, Gastroenterology.

[60]  P. Pelosi,et al.  Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2 , 2020, Expert review of respiratory medicine.

[61]  M. Niriella,et al.  Challenges for Liver Transplantation During Recovery From the COVID-19 Pandemic: Insights and Recommendations , 2020, Transplantation Proceedings.

[62]  S. Ng,et al.  Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization , 2020, Gastroenterology.

[63]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[64]  C. Beyrer,et al.  Assessing differential impacts of COVID-19 on black communities , 2020, Annals of Epidemiology.

[65]  Yuhao Zhang,et al.  New understanding of the damage of SARS-CoV-2 infection outside the respiratory system , 2020, Biomedicine & Pharmacotherapy.

[66]  M. Diamond,et al.  TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes , 2020, bioRxiv.

[67]  R. Panaccione,et al.  Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period , 2020, The Lancet Gastroenterology & Hepatology.

[68]  Huji Xu,et al.  Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process , 2020, Gut.

[69]  A. Amato,et al.  Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study , 2020, Gut.

[70]  Hyeshik Chang,et al.  The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.

[71]  Zhenhua Zhang,et al.  The establishment of reference sequence for SARS‐CoV‐2 and variation analysis , 2020, Journal of medical virology.

[72]  Bing Han,et al.  COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission , 2020, Gastroenterology.

[73]  Lingxi Jiang,et al.  Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests , 2020, International Journal of Infectious Diseases.

[74]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[75]  M. Shi,et al.  Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients , 2020, Emerging microbes & infections.

[76]  M. Llorian,et al.  Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. , 2019, Cell reports.

[77]  Bota Cui,et al.  Improvement of Good’s syndrome by fecal microbiota transplantation: the first case report , 2019, The Journal of international medical research.

[78]  M. Monteiro,et al.  Protective Mechanisms of Butyrate on Inflammatory Bowel Disease. , 2019, Current pharmaceutical design.

[79]  Andrew W. Brooks,et al.  Gut microbiota diversity across ethnicities in the United States , 2018, bioRxiv.

[80]  D. Littman,et al.  Segmented Filamentous Bacteria Provoke Lung Autoimmunity by Inducing Gut-Lung Axis Th17 Cells Expressing Dual TCRs. , 2017, Cell host & microbe.

[81]  Jun Sun,et al.  Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. , 2017, Clinical therapeutics.

[82]  J. O'Sullivan,et al.  The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation , 2016, Front. Cell. Infect. Microbiol..

[83]  B. Marsland,et al.  The Gut-Lung Axis in Respiratory Disease. , 2015, Annals of the American Thoracic Society.

[84]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[85]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[86]  K. Spindler,et al.  Viral disruption of the blood-brain barrier. , 2012, Trends in microbiology.

[87]  T. Macdonald,et al.  Emerging immunological targets in inflammatory bowel disease. , 2011, Current opinion in pharmacology.

[88]  Liping Zhao,et al.  Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers , 2011, The ISME Journal.

[89]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[90]  T. Macdonald,et al.  Immunity, Inflammation, and Allergy in the Gut , 2005, Science.

[91]  D. Mccole,et al.  Every breath you take: Impacts of environmental dust exposure on intestinal barrier function–from the gut-lung axis to COVID-19 , 2021, American journal of physiology. Gastrointestinal and liver physiology.

[92]  A. Fischer,et al.  Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. , 2011, Journal of Alzheimer's disease : JAD.